| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/10-1/50 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Interleukin-12 receptor subunit beta-2, IL-12 receptor subunit beta-2, IL-12R subunit beta-2, IL-12R-beta-2, IL-12RB2, IL12RB2 |
| Entrez GeneID | 3595 |
| WB Predicted band size | 97.1kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | This IL12_2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 756-783 amino acids from the C-terminal region of human IL12_2. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于 **IL12RB2抗体** 的假设性参考文献示例(实际文献需通过数据库验证)：
---
1. **文献名称**：*Targeting IL-12 Receptor Beta2 in Autoimmune Inflammation: A Novel Therapeutic Antibody Approach*
**作者**：Cooper, H., et al.
**摘要**：研究开发了一种靶向IL12RB2的单克隆抗体，通过阻断IL-12信号通路抑制Th1细胞介导的炎症反应，在实验性自身免疫性脑脊髓炎(EAE)模型中显著减轻疾病严重程度。
2. **文献名称**：*Structural Insights into IL-12RB2 Epitopes for Antibody Development*
**作者**：Zhang, L., et al.
**摘要**：通过X射线晶体学解析IL12RB2胞外结构域，鉴定出关键抗原表位，为设计高亲和力治疗性抗体提供结构基础，增强对IL-12/IL-23通路的靶向抑制。
3. **文献名称**：*Anti-IL12RB2 Antibody Enhances NK Cell Activity in Tumor Microenvironment*
**作者**：Smith, J., et al.
**摘要**：证明抗IL12RB2抗体可通过调节NK细胞活性和肿瘤微环境中的免疫抑制因子，抑制黑色素瘤生长，并与PD-1抗体联用展现协同抗肿瘤效果。
4. **文献名称**：*IL12RB2 Antibody Therapy in Chronic Inflammatory Bowel Disease*
**作者**：Müller, R., et al.
**摘要**：临床前研究表明，靶向IL12RB2的人源化抗体可减少肠道Th1炎症细胞浸润，缓解结肠炎模型症状，提示其在克罗恩病等疾病中的治疗潜力。
---
如需真实文献，建议通过 **PubMed/Google Scholar** 检索关键词：
`IL12RB2 antibody therapeutic`, `IL-12 receptor beta2 blockade`。
IL-12 is a pro-inflammatory cytokine produced by antigen-presenting cells, playing a pivotal role in bridging innate and adaptive immunity. It consists of two subunits, p35 and p40. forming a heterodimer (IL-12p70) that activates T cells and natural killer cells via the IL-12 receptor (IL-12R), promoting Th1 differentiation and interferon-gamma (IFN-γ) production. Dysregulated IL-12 signaling is implicated in autoimmune and chronic inflammatory diseases, such as psoriasis, inflammatory bowel disease (IBD), and multiple sclerosis.
IL-12-targeted therapies, including monoclonal antibodies (mAbs), have been developed to modulate this pathway. IL12_2 antibody likely refers to a therapeutic mAb designed to neutralize IL-12 or its receptor. Early anti-IL-12 antibodies focused on blocking the p40 subunit, shared with IL-23. but this approach inadvertently inhibited both cytokines, leading to mixed efficacy and safety profiles. IL12_2 may represent a next-generation antibody engineered for enhanced specificity, selectively targeting IL-12p70 or its receptor without cross-reacting with IL-23. Such specificity could reduce off-target effects while maintaining therapeutic benefits in Th1-driven pathologies.
Preclinical and clinical studies of IL-12-targeting antibodies have shown promise in suppressing inflammation and autoimmune responses. However, challenges remain in balancing efficacy with immune suppression risks. IL12_2’s development likely aims to address these limitations, offering a tailored approach for diseases where IL-12 is a primary driver. Ongoing research continues to refine its pharmacokinetics, epitope binding, and safety profile to optimize clinical outcomes.
×
